FOLH1 (folate hydrolase 1), also known as prostate-specific membrane antigen (PSMA), is an established prostate cancer cell marker that is widely used in diagnosis and therapies. PSMA is a type II transmembrane glycoprotein with most of its mass exposed on the cell surface. In contrast to its modest expression in healthy prostates, brains, and salivary glands, PSMA is abundantly present in the intestines. The extracellular domain of PSMA acts as a glutamate carboxypeptidase on different substrates, including the nutrient folate (in intestines) and the neuropeptide N-acetyl-l-aspartyl-l-glutamate (in brains). Mutations or aberrantly expression of FOLH1 can result in impaired intestinal absorption of dietary folates or glutamate excitotoxicity in the brain, respectively.

Although PSMA is expressed in many cancer types (e.g. bladder, brain, kidney, lung, thyroid gland), its overexpression correlated with progression and metastasis of prostate cancer suggesting that PSMA may play a functional role in prostate cancer progression. Read the report

FOLH1 recombinant protein TP318310	Anti-FOLH1 UltraMAB UM570025	Ab for Flow Cytometry AM03114PU-N